Preliminary safety, pharmacokinetic, and pharmacodynamic results from a phase 1b/2 dose-escalation and cohort-expansion study of the noncovalent, reversible Bruton's tyrosine kinase inhibitor (BTKi), vecabrutinib, in B-lymphoid malignancies Meeting Abstract
| Authors: | Allan, J. N.; Wierda, W. G.; Patel, K.; O'Brien, S. M.; Mato, A. R.; Davids, M. S.; Furman, R. R.; Pagel, J. M.; Fox, J. A.; Ward, R.; Taverna, P.; Brown, J. R. |
| Abstract Title: | Preliminary safety, pharmacokinetic, and pharmacodynamic results from a phase 1b/2 dose-escalation and cohort-expansion study of the noncovalent, reversible Bruton's tyrosine kinase inhibitor (BTKi), vecabrutinib, in B-lymphoid malignancies |
| Meeting Title: | 60th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 132 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2018 Dec 1-4 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2018-11-29 |
| Language: | English |
| ACCESSION: | WOS:000454842800291 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood-2018-99-116382 |
| Notes: | Meeting Abstract: 3141 -- Source: Wos |
